Drugs / AGS62P1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02864290 | Nov 2016 → Sep 2020 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGS62P1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297893 ↗ |
| Known as | ASP1235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864290 ↗ |